Placeholder Banner

BIO Premieres New Ad Highlighting the Value of Biomedical Innovation

February 8, 2016

Washington, D.C. (February 8, 2016) – The Biotechnology Innovation Organization (BIO) today launched a new ad focused on the value of biomedical innovation, highlighting the most compelling benefits of biomedical research – giving patients time to live fuller lives. The ad serves as a cornerstone for BIO’s new Value Campaign, which will provide an avenue for the biotechnology sector to highlight the value of biomedical innovation and includes a new “Time Is Precious” website.

“With this effort, BIO is advancing the national public policy debate over the cost and value of medicine, shining a spotlight on the fact that innovative, life-saving medicines provide benefits far beyond their costs,” said BIO President & CEO Jim Greenwood. “It’s time for the public to hear the voices of those who are benefitting from medical breakthroughs and those who are bringing these breakthroughs to market.”

Through the campaign, the public will see that today’s innovative life-enhancing medicines save and extend lives, improve quality of life and drive value to patients and the healthcare system as a whole. The ad represents just the beginning of BIO’s campaign, which includes a new “Time Is Precious” website.

“Thanks to biomedical breakthroughs we have seen HIV/AIDS death rates drop by 85% since 1995; heart disease death rates have decreased by 30% between 2001 and 2011, and cancer death rates are down 22% since 1991. America’s innovative biopharmaceutical companies are tackling some of our most unrelenting scientific challenges head-on and are delivering new, high-value cures and treatments that are saving and extending the lives of patients and giving them precious time to lead fuller lives,” said Greenwood.

The Value of Medicine advertisement can be viewed HERE.For more information on the advertisement or BIO’s Value Campaign, please visit: http://timeisprecious.life

###

Discover More
BIO to Transition Agricultural and Environmental Biotech Workstreams  Key Senior Hires Bolster Focus on Regulatory Affairs, Emerging Companies   and Economic Growth   Washington, DC, May 28, 2025 – The Biotechnology Innovation…
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…
WASHINGTON, DC, April 8, 2025 – Today, the National Security Commission on Emerging Biotechnology (NSCEB), a bipartisan legislative commission established by Congress, issued its much-anticipated report detailing how the United States risks…